Following the Completion of the Transition of GLASSIA Manufacturing, Kamada will Transfer the Product’s US Biologics License Application (BLA) to Takeda; Expected to Occur by End of 2021. Kamada to Receive from Takeda a Payment of $2 Million for the BLA Transfer. Final Sales-Based Milestone Payment of $5 Million Due to Kamada under the License […]
As Previously Reported, 11 of the 12 Patients Recovered and were Discharged from Hospital; Seven Patients were Discharged at or Before Day 5 and the Remaining Four Patients were Discharged by Day 9 of Treatment. No Infusion-Related Reactions or Adverse Events Considered Related to Study Drug were Observed. Company Continues to Supply its IgG Product […]
REHOVOT, Israel – March 9, 2021 – Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived biopharmaceutical company, announced today that Amir London, Chief Executive Officer, will present a corporate overview at the inaugural Jefferies Virtual Global Plasma Summit, being held on March 11, 2021. Mr. London is scheduled to present at 9:35 a.m. Eastern Time. […]
Rehovot, Israel, February 24, 2021 – Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020, with the U.S. Securities and Exchange Commission (the “SEC”). The annual report, including the Company’s audited consolidated financial statements, […]
Full-Year 2020 Revenues were $133.2 Million, In-Line with the Company’s Guidance; Adjusted EBITDA for 2020 was $25.1 Million Kamada EntersS. Plasma Collection Market Through Acquisition of an FDA-Approved Facility, Furthering its Strategic Goal of Becoming a Fully Integrated Specialty Plasma Company Focused on Growing its Hyperimmune IgG Portfolio Israeli Ministry of Health (IMOH) Initiated Treatment […]
Rehovot, Israel, February 3, 2021 – Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2020, prior to the open of the U.S. financial markets on Wednesday, February 10, 2021. Kamada management will host an investment community […]
Kamada Acquires FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in Texas, USA Transaction Represents Kamada’s Entry into U.S. Plasma Collection Market and Advances the Company’s Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company Blood and Plasma Research, Inc. Primarily Focuses on Collecting Hyper-Immune Plasma, and Kamada Plans to Significantly […]
The Three Products Are Expected to Be Launched, Subject to Israeli Ministry of Health Approval, Between 2022 and 2024 Potential Collective Maximum Sales of the Three Products in the Israeli Market is Estimated at $5-$7 Million Annually These Sales Are in Addition to the Potential $20-$30 Million from the Recently Licensed Alvotech Biosimilar Portfolio REHOVOT, […]
Rehovot, Israel, January 5, 2021 — Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it has been selected as one of 10 winners of the Genesis Prize Foundation (GPF) Start-Up Nation Central (SNC) competition recognizing Israeli companies working to combat coronavirus and the damage of future pandemics. Based on its development […]
REHOVOT, Israel – December 21, 2020 — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology […]